Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 20/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18395243 | 0.78 | NOTUM (1.00) | NOTUM | |
| SCHEMBL2291570 | 0.78 | NOTUM (0.67) | NOTUM | |
| SCHEMBL13050395 | 0.78 | NOTUM (0.67) | NOTUM | |
| SCHEMBL8270247 | 0.78 | NOTUM (1.00) | NOTUM | |
| SCHEMBL13874852 | 0.77 | NOTUM (0.54) | NOTUM | |
| SCHEMBL5542637 | 0.76 | NOTUM (1.00) | NOTUM | |
| SCHEMBL13050398 | 0.75 | NOTUM (0.51) | NOTUM | |
| SCHEMBL18395694 | 0.74 | NOTUM (1.00) | NOTUM | |
| SCHEMBL4392841 | 0.74 | NOTUM (0.68) | NOTUM | |
| SCHEMBL19736897 | 0.74 | NOTUM (0.74) | NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292282-A1 | SYNTHESIS AND CRYSTALLINE FORMS OF CB-1 ANTAGONIST/INVERSE AGONIST | MERCK & CO., INC. | 2010-11-18 | — | — | US | disclosed |
| US-20100292282-A1 | SYNTHESIS AND CRYSTALLINE FORMS OF CB-1 ANTAGONIST/INVERSE AGONIST | MERCK & CO., INC. | 2010-11-18 | — | — | US | disclosed |
| WO-2009054923-A2 | SYNTHESIS AND CRYSTALLINE FORMS OF CB-1 ANTAGONIST/INVERSE AGONIST | MERCK & CO., INC. (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292282-A1 | SYNTHESIS AND CRYSTALLINE FORMS OF CB-1 ANTAGONIST/INVERSE AGONIST | CNR1, ARRB1, CNR2 | NOTUM 3895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.